Elevance Health, Inc.

Valuation Analysis

About the Company

Elevance Health, Inc. en bref

Elevance Health, Inc. (ELV) is currently trading at 338,63 € with a market capitalization of 73,5 Md €. The trailing P/E ratio stands at 16.47x, with a forward P/E of 13.28x. The 52-week range spans from 238,61 € to 372,23 €; the current price is 9% below the yearly high. Year-over-year revenue growth stands at +2.6%. The net profit margin stands at 2.62%.

💰 Dividende

Elevance Health, Inc. pays an annual dividend of 6,00 € per share, representing a yield of 1.77%. The payout ratio stands at 29.03%.

📊 Avis des analystes

21 analystes évaluent Elevance Health, Inc. (ELV) au consensus : Acheter. L'objectif de cours moyen est de 362,49 €, soit un potentiel de +7.05% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 288,55 € à 434,14 €.

Elevance Health, Inc. : la thèse d'investissement en détail

Elevance Health, Inc. (ELV) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

Revenue growth has slowed to just 2.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy. With a net margin of just 2.62%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss.

Valorisation en contexte

The PEG ratio at 1.46 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 9.52x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 13.28x is meaningfully below the trailing 16.47x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Elevance Health, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.